131 related articles for article (PubMed ID: 36799122)
1. Neurocognitive outcomes of children with osteosarcoma treated with methotrexate.
Shima H; Sato S; Takimoto T; Sakai M; Hashida N; Isshiki K; Shimada H
Pediatr Int; 2023 Jan; 65(1):e15487. PubMed ID: 36799122
[No Abstract] [Full Text] [Related]
2. Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.
Scott JR; Ward DA; Crews KR; Panetta JC; Navid F
Pediatr Blood Cancer; 2014 Feb; 61(2):373-5. PubMed ID: 23955991
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate in fibroblastic osteosarcoma.
Chowbay B; Siong KK
Ann Pharmacother; 2001 Dec; 35(12):1669. PubMed ID: 11793640
[No Abstract] [Full Text] [Related]
4. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma.
Edelmann MN; Daryani VM; Bishop MW; Liu W; Brinkman TM; Stewart CF; Mulrooney DA; Kimberg C; Ness KK; Cheung YT; Srivastava DK; Robison LL; Hudson MM; Krull KR
JAMA Oncol; 2016 Feb; 2(2):201-8. PubMed ID: 26583357
[TBL] [Abstract][Full Text] [Related]
5. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature.
Bielack SS; Beron G; Winkler K
Cancer; 1997 Aug; 80(3):516-8. PubMed ID: 9241087
[No Abstract] [Full Text] [Related]
6. Can high dose methotrexate be continued after severe hypersensitivity reaction?
Marzollo A; Bisogno G
Pediatr Blood Cancer; 2014 Jun; 61(6):1139. PubMed ID: 24265186
[No Abstract] [Full Text] [Related]
7. The classic: recent advances in chemotherapy of metastatic osteogenic sarcoma. 1972.
Jaffe N
Clin Orthop Relat Res; 2005 Sep; 438():19-21. PubMed ID: 16131864
[No Abstract] [Full Text] [Related]
8. For Patients With Cancer, Cure Is Not Enough.
Effinger KE; Link MP
JAMA Oncol; 2016 Feb; 2(2):176-8. PubMed ID: 26584335
[No Abstract] [Full Text] [Related]
9. The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma.
Kawai A; Sugihara S; Kunisada T; Hamada M; Inoue H
Arch Orthop Trauma Surg; 1996; 115(2):68-70. PubMed ID: 9063854
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived osteosarcoma cells are resistant to methotrexate.
Dos Santos Cavalcanti A; Meohas W; Ribeiro GO; de Sá Lopes AC; Gholamin S; Razavi M; Hanae Kasai Brunswick T; Avan A; Matheus Guimarães JA; Leite Duarte ME; Kahn SA
PLoS One; 2017; 12(9):e0184891. PubMed ID: 28934267
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate.
Hosain F; Spencer RP; Couthon HM; Sturtz GL
J Nucl Med; 1996 Jan; 37(1):105-7. PubMed ID: 8543977
[TBL] [Abstract][Full Text] [Related]
12. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
[TBL] [Abstract][Full Text] [Related]
13. Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate.
Shinozaki T; Watanabe H; Tomidokoro R; Yamamoto K; Horiuchi R; Takagishi K
Med Pediatr Oncol; 2000 Mar; 34(3):226-8. PubMed ID: 10696135
[No Abstract] [Full Text] [Related]
14. High-dose methotrexate is effective in osteosarcoma so what is the problem?
Cohen IJ
J Pediatr Hematol Oncol; 2009 Dec; 31(12):892-4. PubMed ID: 19887958
[No Abstract] [Full Text] [Related]
15. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
16. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
17. Outpatient high-dose methotrexate: proceed with extreme caution, if at all.
Womer RB
Pediatr Blood Cancer; 2010 Dec; 55(7):1250-1. PubMed ID: 20981687
[No Abstract] [Full Text] [Related]
18. Reduced methotrexate clearance and renal impairment in a boy with osteosarcoma and earlier undetected autosomal dominant polycystic kidney disease (ADPKD).
Alberer M; Hoefele J; Bergmann C; Hartrampf S; Hilberath J; Pawlita I; Albert MH; Benz MR; Weber LT; Schmid I
J Pediatr Hematol Oncol; 2010 Nov; 32(8):e314-6. PubMed ID: 20921908
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
[TBL] [Abstract][Full Text] [Related]
20. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma.
Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N
J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
